StartNATCOPHARM • NSE
add
Natco Pharma Ltd.
Seneste lukkekurs
1.389,20 ₹
Dagsinterval
1.365,60 ₹ - 1.403,85 ₹
Årsinterval
724,20 ₹ - 1.639,00 ₹
Markedsværdi
250,57 mia. INR
Gns. volumen
843,82 t
P/E-værdi
15,31
Udbytteprocent
0,39 %
Primær børs
NSE
Markedsnyheder
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
(INR) | jun. 2024info | År til år-ændring |
---|---|---|
Indtægt | 13,63 mia. | 19,47 % |
Driftsudgifter | 4,22 mia. | 3,11 % |
Nettoindtægt | 6,68 mia. | 59,05 % |
Overskudsgrad | 49,06 | 33,13 % |
Earnings per share | 37,32 | 60,45 % |
EBITDA | 8,07 mia. | 40,06 % |
Effektiv afgiftssats | 16,81 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
(INR) | jun. 2024info | År til år-ændring |
---|---|---|
Kontanter og korttidsinvesteringer | 18,49 mia. | 59,13 % |
Samlede aktiver | — | — |
Samlede passiver | — | — |
Samlet egenkapital | 58,53 mia. | — |
Shares outstanding | 179,13 mio. | — |
Kurs/indre værdi | 4,25 | — |
Afkast af aktiver | — | — |
Afkast af kapital | 30,55 % | — |
Pengestrøm
Nettoændring i likviditet
(INR) | jun. 2024info | År til år-ændring |
---|---|---|
Nettoindtægt | 6,68 mia. | 59,05 % |
Pengestrøm fra drift | — | — |
Pengestrøm fra investering | — | — |
Pengestrøm fra finansiering | — | — |
Nettoændring i likviditet | — | — |
Fri pengestrøm | — | — |
Om
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad with a presence in formulation and active pharmaceutical ingredients in both domestic and international markets. The company also manufactures Agro chemical products. It is a major producer of branded oncology medicines cardiology, diabetology and other pharma specialty drugs. The company specialises in producing complex medicines at affordable prices. The company has a presence in 50+ countries. NATCO is a science driven company and focuses on limited competition molecules in the US .The company’s pharma division has 5 manufacturing facilities, 2 API and intermediate manufacturing facilities and the crop health sciences division has one formulation and one technical manufacturing facility. The company boasts of having a talent pool of 450+ scientists working out of two research centers in India.
Across the globe, cancer treatment saw a sea change in early 2000s in terms of screening, diagnosis, molecular pathology, targeted therapies, immunotherapies, Bone Marrow Transplants, and supportive care. Wikipedia
Administrerende direktør
Grundlagt
1981
Hovedkvarter
Website
Ansatte
4.016